Hsin-Wei Chen, Ph.D.
Vaccine Research and Development Center
EDUCATIONPh.D., Department of Agricultural Chemistry, National Taiwan University, Taiwan, 1997
M.S., Department of Agricultural Chemistry, National Taiwan University, Taiwan, 1991
B.S., Department of Agricultural Chemistry, National Taiwan University, Taiwan, 1989
PROFESSIONAL EXPERIENCESAssistant Investigator, Vaccine Research and Development Center, National Health Research Institutes, Taiwan (2004-present)
Adjunct Assistant Professor, Department of Biotechnology, Ming Chuan University, Taiwan (2004-present)
Assistant Investigator, Division of Cancer Research, National Health Research Institutes, Taiwan (2002-2003)
Postdoctoral Fellow, Division of Cancer Research, National Health Research Institutes, Taiwan (2000-2002)
Adjunct Assistant Professor, Department of Environmental Engineering, National Yi-Lan Colleage of Agricultures and Engineering, Taiwan (1999-2000)
Postdoctoral Fellow, Institute of Biomedical Sciences, Academia Sinica, Taiwan (1997-2000)
RESEARCH INTERESTSDr. Chen's major interest is to develop prophylactic or therapeutic vaccines. His current research is working on the development of dengue vaccine, discovery of human CTL epitopes to develop therapeutic cancer vaccine and Tnc17 immune-regulatory mechanism.
RESEARCH ACTIVITIES & ACCOMPLISHMENTSDr. Chen's has established platform technology for determination of T and B cell immune responses in Vaccine R&D Center. These technologies could be applied to clinical immune monitoring and vaccine development. In addition, Dr. Chen identified a distinct CD8 subset which secret cytokine IL-17 but has no cytotoxic activity. He named this subset T cells as T noncytotxic-17 (Tnc17). This is the first report in the world.
SELECTED PUBLICATIONS1.Liu SJ, Tsai JP, Shen CR, Sher YP, Hsieh CL, Yeh YC, Chou AH, Chang SR, Hsiao KN, Yu FW, Chen HW*. Induction of a Distinct CD8 Tnc17 Subset by Transforming Growth Factor-? and Interleukin-6. Journal of Leukocyte Biology. 82: 354-60, 2007. (*=Corresponding Author)
2.Chen HW, Liu SJ, Chong P, Sia C. The Development and Application of HLA Tetramers in the Detection, Characterization and Therapy of Type 1 Diabetes Mellitus. Rev. Diabetic studies. 3: 51-6, 2007.
3.Lien SP, Shih YP, Chen HW, Tsai JP , Leng CH, Lin MH, Lin LH, Liu SY, Chou AH, Chang YW, Chen YM, Chong P, Liu SJ. Identification of Synthetic Vaccine Candidates against SARS CoV Infection. Biochem. Biophy. Res. Commun. 358: 716-21, 2007.
4.Cheng ML, Chen HW, Tsai JP, Lee YP, Shih YC, Chang CM, Ting CC. Clonal restriction of the expansion of antigen specific CD8+ memory T cells by transforming growth Factor-?. J. Leu. Bio. 79:1033-1042, 2006.
5.Tsai JP, Chen HW*, Cheng ML, Liu HK, Lee YP, Hsieh CL, Luh KT, Wu CW, Hsu LH, Chao TY, Wang WH, Chang CM, Ting CC. Analysis of host versus tumor interaction in cancer patients: opposing role of transforming growth factor-b1 and interleukin-6 in the development of in situ tumor immunity. Immunobiology. 210:661-671, 2005. (*=Corresponding Author)
6.Chen HW, Lee YP, Chung YF, Shih YC, Tsai JP, Tao MH, Ting CC. Inducing long-term survival with lasting anti-tumor immunity in treating B cell lymphoma by a combined dendritic cell-based and hydrodynamic plasmid-encoding IL-12 gene therapy. Int. Immunol. 15:427-435, 2003.
7.Chen HW, Huang HI, Lee YP, Chen LL, Liu HK, Cheng ML, Tsai JP, Tao MH, Ting CC. Linkage of CD40L to a self-tumor antigen enhances the antitumor immune responses of dendritic cells-base treatment. Cancer Immuno. Immunother. 51:341-348, 2002.